SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013

被引：0
作者：
S. Del Barco
E. Ciruelos
I. Tusquets
M. Ruiz
A. Barnadas
机构：
[1] Hospital Dr. Josep Trueta,Medical Oncology Department
[2] Institut Català d’Oncologia (ICO),Medical Oncology Department
[3] Hospital Universitario,Medical Oncology Department
[4] Hospital de Parc de Salut Mar,Medical Oncology Department
[5] Hospital Virgen del Rocío,Medical Oncology Department
[6] Hospital de la Santa Creu i Sant Pau,undefined
来源：
Clinical and Translational Oncology | 2013年 / 15卷
关键词：
Breast cancer; Guidelines; Adjuvant therapy; Prognostics factors; Ending treatment; Follow-up guideline;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The purpose of this article is to update our previous work on the treatment and follow-up in early breast cancer. In this new version we have classified a treatment by immunohistochemistry subtypes of breast cancer. Latest advances in the management of this disease have been compiled, either in the adjuvant and neoadjuvant setting or chemotherapy and hormonal treatment. This review is presented in an easy way for oncologist, fellows and for other specialties.
引用
收藏
页码：1011 / 1017
页数：6
相关论文
共 84 条
[1]  
Davies Ch(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet. 365 1687-1717
[2]  
Pan H(2012)Comparison between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100000 women in 123 randomised trials Lancet 379 432-44
[3]  
Godwin J(2013)Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 805-816
[4]  
Gray R(2002)Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women for early breast cancer: first results of the ATAC randomised trial Lancet 359 2131-2139
[5]  
Arriagada R(2005)A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747-2757
[6]  
Raina V(2004)A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081-1092
[7]  
Coombes Ch(2009)Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 361 776-76
[8]  
Hall E(2010)Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen J Clin Oncol 28 509-518
[9]  
Gibson LJ(2008)Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials J Clin Oncol 26 44-53
[10]  
Paridaens R(2005)Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 2302-2313
123456789